View in EDS HTML Full Text PDF Full Text

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.

Saved in:
Bibliographic Details
Title: SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
Authors: McGovern BH; Seres Therapeutics, Cambridge, Massachusetts, USA., Ford CB; Seres Therapeutics, Cambridge, Massachusetts, USA., Henn MR; Seres Therapeutics, Cambridge, Massachusetts, USA., Pardi DS; Mayo Clinic, Gastroenterology Division, Rochester, Minnesota, USA., Khanna S; Mayo Clinic, Gastroenterology Division, Rochester, Minnesota, USA., Hohmann EL; Massachusetts General Hospital, Infectious Diseases Division, Boston, Massachusetts, USA., O'Brien EJ; Seres Therapeutics, Cambridge, Massachusetts, USA., Desjardins CA; Seres Therapeutics, Cambridge, Massachusetts, USA., Bernardo P; Seres Therapeutics, Cambridge, Massachusetts, USA., Wortman JR; Seres Therapeutics, Cambridge, Massachusetts, USA., Lombardo MJ; Seres Therapeutics, Cambridge, Massachusetts, USA., Litcofsky KD; Seres Therapeutics, Cambridge, Massachusetts, USA., Winkler JA; Seres Therapeutics, Cambridge, Massachusetts, USA., McChalicher CWJ; Seres Therapeutics, Cambridge, Massachusetts, USA., Li SS; Seres Therapeutics, Cambridge, Massachusetts, USA., Tomlinson AD; Seres Therapeutics, Cambridge, Massachusetts, USA., Nandakumar M; Seres Therapeutics, Cambridge, Massachusetts, USA., Cook DN; Seres Therapeutics, Cambridge, Massachusetts, USA., Pomerantz RJ; Seres Therapeutics, Cambridge, Massachusetts, USA., Auninš JG; Seres Therapeutics, Cambridge, Massachusetts, USA., Trucksis M; Seres Therapeutics, Cambridge, Massachusetts, USA.
Source: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Jun 15; Vol. 72 (12), pp. 2132-2140.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32255488
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22McGovern+BH%22">McGovern BH</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Ford+CB%22">Ford CB</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Henn+MR%22">Henn MR</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Pardi+DS%22">Pardi DS</searchLink>; Mayo Clinic, Gastroenterology Division, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Khanna+S%22">Khanna S</searchLink>; Mayo Clinic, Gastroenterology Division, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Hohmann+EL%22">Hohmann EL</searchLink>; Massachusetts General Hospital, Infectious Diseases Division, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22O'Brien+EJ%22">O'Brien EJ</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Desjardins+CA%22">Desjardins CA</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Bernardo+P%22">Bernardo P</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Wortman+JR%22">Wortman JR</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Lombardo+MJ%22">Lombardo MJ</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Litcofsky+KD%22">Litcofsky KD</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Winkler+JA%22">Winkler JA</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22McChalicher+CWJ%22">McChalicher CWJ</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Li+SS%22">Li SS</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Tomlinson+AD%22">Tomlinson AD</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Nandakumar+M%22">Nandakumar M</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Cook+DN%22">Cook DN</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Pomerantz+RJ%22">Pomerantz RJ</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Auninš+JG%22">Auninš JG</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Trucksis+M%22">Trucksis M</searchLink>; Seres Therapeutics, Cambridge, Massachusetts, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229203213%22">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</searchLink> [Clin Infect Dis] 2021 Jun 15; Vol. 72 (12), pp. 2132-2140.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9203213 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1537-6591 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210584838%22">10584838 </searchLink><i>NLM ISO Abbreviation: </i>Clin Infect Dis <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32255488
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/cid/ciaa387
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2132
    Titles:
      – TitleFull: SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: McGovern BH
      – PersonEntity:
          Name:
            NameFull: Ford CB
      – PersonEntity:
          Name:
            NameFull: Henn MR
      – PersonEntity:
          Name:
            NameFull: Pardi DS
      – PersonEntity:
          Name:
            NameFull: Khanna S
      – PersonEntity:
          Name:
            NameFull: Hohmann EL
      – PersonEntity:
          Name:
            NameFull: O'Brien EJ
      – PersonEntity:
          Name:
            NameFull: Desjardins CA
      – PersonEntity:
          Name:
            NameFull: Bernardo P
      – PersonEntity:
          Name:
            NameFull: Wortman JR
      – PersonEntity:
          Name:
            NameFull: Lombardo MJ
      – PersonEntity:
          Name:
            NameFull: Litcofsky KD
      – PersonEntity:
          Name:
            NameFull: Winkler JA
      – PersonEntity:
          Name:
            NameFull: McChalicher CWJ
      – PersonEntity:
          Name:
            NameFull: Li SS
      – PersonEntity:
          Name:
            NameFull: Tomlinson AD
      – PersonEntity:
          Name:
            NameFull: Nandakumar M
      – PersonEntity:
          Name:
            NameFull: Cook DN
      – PersonEntity:
          Name:
            NameFull: Pomerantz RJ
      – PersonEntity:
          Name:
            NameFull: Auninš JG
      – PersonEntity:
          Name:
            NameFull: Trucksis M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 06
              Text: 2021 Jun 15
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1537-6591
          Numbering:
            – Type: volume
              Value: 72
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
              Type: main
ResultId 1